Congress faces a critical vote to avert a prolonged shutdown, while newly released documents shed light on the Minneapolis shooting involving immigration officers and the Epstein case continues to reverberate.
A highly sensitive whistleblower complaint alleging misconduct by Director of National Intelligence Tulsi Gabbard has been locked within the intelligence bureaucracy since May, with Congress aware of its existence but blocked from reviewing it amid accusations of obstruction.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Google is rolling out a significant update to its Chrome browser, embedding advanced Gemini AI capabilities directly into the user interface. The move signals a strategic push to make AI a central, everyday tool for web navigation and tasks.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.
New data ranks the greater Hartford area as the fourth most competitive housing market in the U.S., with a critically low 3.3-month supply driving projections of a 17.1% surge in median home prices this year.
Award-winning builder Martin Daly is closing his Scottish business for a new life in Switzerland, joining a growing wave of tradespeople leaving the UK. Industry leaders warn that tax policies, rising costs, and a lack of support for small firms are crippling the sector and jeopardising national housing targets.
Global commodity markets opened the new week and month deep in negative territory, with the energy sector plummeting an average of 7.3% and grains facing headwinds from shifting trade flows and seasonal pressures.
A new study highlights a persistent gap between finance and cybersecurity leaders on strategic alignment, risk measurement, and investment priorities, despite widespread recognition of cyber threats.
The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Canadian junior miner G2 Goldfields Inc. (TSX: GTWO), despite recent losses, is projected by analysts to reach profitability within two years, backed by aggressive growth forecasts and a debt-free balance sheet.
As Bob Iger prepares to step down, he highlights a 'healthy competition' between Disney's resurgent parks and its entertainment division to become the company's primary profit driver, with the board close to naming his successor.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
